"Operating profits more than trebled to $3.8bn, reflecting a positive mix impact as lower margin COVID vaccine sales were replaced by high value treatments for cancer and rare disease.
Free cash flow of $8.7bn was up 79% and net debt fell from $24.3bn to $22.9bn."